Regulatory fears ensnare more stocks in Xi Jinping’s new china

China’s rolling regulatory crackdown on unfair has found new targets, with liquor makers, cosmetics firms and online pharmacies in the cross-hairs.

A slew of commentary and reports in state media called for better oversight of these industries on Friday to protect consumers, adding to earlier rulings targeting private tuition firms and technology firms as President seeks to address inequality.

Distillers led a decline in the benchmark CSI 300 Index after it was reported that liquor producers will meet the regulator over market order. The nation’s biggest liquor maker Kweichow Moutai Co. plunged as much as 4.3%. Online health care stocks also dropped, with JD Health Inc. down 13% after the People’s Daily urged more protection and guarantee of prescription drugs sold through the internet.

The plunge in these new sectors comes at a time when investors have become super-sensitive about which companies will be the target next of official scrutiny. Over the past weeks, there’s been selloffs in everything from private tutoring firms to e-cigarettes, games and infant formula amid a new regulatory drive stressing social equality.


“With regulation worries and the beginning of a downturn in economic growth, it’s extremely hard to make money right now,” said Hou Anyang, fund manager at Frontsea Asset Management in Shenzhen. “At this rate even the winning stocks in electric vehicles and chips may not stay strong much longer.”

State media also turned up the heat on the cosmetic surgery industry, calling for better oversight in the face of incomplete regulations and growing medical disputes. Ping An Healthcare & Technology Co. dropped by as much as 17%, its biggest intraday decline ever.

Foreigners net sold 6.5 billion yuan ($1 billion) worth of mainland shares via the trading links as of the mid-day break in Shanghai and Shenzhen, after dumping 10.7 billion yuan on Thursday, the most this month.

Meanwhile redemptions from China equity products could be picking up pace as the year-to-date underperformance of some funds is “causing additional difficulties in recapturing substantial inflows in the short term,” Morgan Stanley quant analysts wrote in a note this week.

Dear Reader,

Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.

As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.

Support quality journalism and subscribe to Business Standard.

Digital Editor

Read More: Regulatory fears ensnare more stocks in Xi Jinping’s new china

You might also like